Publications by authors named "Agnes Mattsson"

Claim this Profile
F
Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?
Agnes Mattsson, Jeanette Lundin, Tom A Mulder, Sandra E Sylvan, Marzia Palma

Blood Neoplasia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
Agnes Mattsson, Sandra Eketorp Sylvan, Per Axelsson, Fredrik Ellin, Christian Kjellander

Eur J Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Agnes Mattsson, Sandra E Sylvan, Anna Asklid, Joel Wiggh, Maria Winqvist

Br J Haematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy.
Anna Asklid, Sandra Eketorp Sylvan, Agnes Mattsson, Maria Winqvist, Hemming Johansson

Leuk Lymphoma· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.
Anna Asklid, Maria Winqvist, Sandra Eketorp Sylvan, Agnes Mattsson, Einar Björgvinsson

Leuk Lymphoma· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis